Carl Stefan Fraenkel

Direktor/Vorstandsmitglied bei Akinion Pharmaceuticals AB

52 Jahre

Health Technology

Consumer Services

Profil

Carl Stefan Fraenkel is currently a Director at Akinion Pharmaceuticals AB.
Previously, he worked as Vice President & Head-Business Development at Swedish Orphan Biovitrum AB from 2011 to 2012.
He holds an MBA and a doctorate from Copenhagen Business School, and an undergraduate degree from Chalmers University of Technology.

Aktive Positionen von Carl Stefan Fraenkel

Unternehmen	Position	Beginn
Akinion Pharmaceuticals AB Akinion Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Akinion Pharmaceuticals AB operates as a holding company that focuses on the development of pharmaceutical for the treatment of acute myeloid leukemia. It develops, markets, and sells a product based on Biovitrum’s anti leukemia kinase inhibitor research. It is a drug development that manufactures a lead candidate drug, AKN-028, which is a small molecule kinase inhibitor. The company was founded by Vendela Parrow in 2009 and is headquartered in Solna, Sweden.	Direktor/Vorstandsmitglied	-

Alle aktiven Positionen von Carl Stefan Fraenkel

Ehemalige bekannte Positionen von Carl Stefan Fraenkel

Unternehmen	Position	Ende
SWEDISH ORPHAN BIOVITRUM AB	Corporate Officer/Principal	-

Sehen Sie sich die Erfahrung von Carl Stefan Fraenkel im Detail an

Ausbildung von Carl Stefan Fraenkel

Copenhagen Business School	Doctorate Degree
Chalmers University of Technology	Undergraduate Degree

Erfahrungen
Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Sehen Sie sich die Erfahrung von Carl Stefan Fraenkel im Detail an

Beziehungen

Beziehungen ersten Grades

Unternehmen ersten Grades

Herr

Frau

Aufsichtsräte

Führungskräfte

Sehen Sie sich das persönliche Netzwerk an

Unternehmensverbindungen

Börsennotierte Unternehmen	1
SWEDISH ORPHAN BIOVITRUM AB	Health Technology

Private Unternehmen	1
Akinion Pharmaceuticals AB Akinion Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Akinion Pharmaceuticals AB operates as a holding company that focuses on the development of pharmaceutical for the treatment of acute myeloid leukemia. It develops, markets, and sells a product based on Biovitrum’s anti leukemia kinase inhibitor research. It is a drug development that manufactures a lead candidate drug, AKN-028, which is a small molecule kinase inhibitor. The company was founded by Vendela Parrow in 2009 and is headquartered in Solna, Sweden.	Health Technology